Oral Paclitaxel combination regimen has graduated from this Phase 2 trial in the triple negative breast cancer subgroup of the I-SPY2 Trial

"Separating contenders from
pretenders in breast cancer"
-- ASCO Post
"Blazes a trail in breast cancer"
-- Nature Biotechnology
"A glimpse into the future of
phase II drug development?"
-- NEJM